Table 3.
Absolute and relative differences in mean dose and BED between sequential boost and the simultaneous integrated boost using the same prescribed biologically effective dose with α/β = 10 Gy (BED10) and 3 Gy (BED3) for all structures of the ten studied patients (mean ± SD)
| Dose (Gy) | (SIB10/SEQ–1) × 100 | Dose (Gy) | (SIB3/SEQ–1) × 100 | |||
|---|---|---|---|---|---|---|
| Dose (%) | BED10 (%) | Dose (%) | BED3 (%) | |||
| PTVboost | −1.5 ± 0.7 | −2 ± 1 | 0 ± 1 | −3.0 ± 0.7 | −5 ± 1 | 0 ± 2 |
| PTVbreast | −1.3 ± 0.8 | −2 ± 1 | −3 ± 1 a | −0.6 ± 0.9 | −1 ± 2 | −2 ± 2 a |
| ILung | −0.7 ± 0.4 | −8 ± 4 | −10 ± 4 a | −0.8 ± 0.5 | −9 ± 4 | −11 ± 4 a |
| CBreast | −0.1 ± 0.3 | −6 ± 16 | −6 ± 17 | −0.1 ± 0.3 | −5 ± 15 | −6 ± 16 |
| CLung | −0.1 ± 0.1 | −7 ± 13 | −8 ± 14 | −0.1 ± 0.2 | −6 ± 17 | −7 ± 18 |
| Heartleft b | −0.3 ± 0.5 | −10 ± 16 | −12 ± 16 | −0.2 ± 0.1 | −6 ± 4 | −8 ± 4 a |
| Heartright c | −0.3 ± 0.4 | −12 ± 17 | −14 ± 19 | −0.2 ± 0.6 | −8 ± 24 | −10 ± 25 |
aIndicates a significant difference (p <0.05) between the SEQ and SIB plans in term of BED
bGroup of 6 patients with left-sided breast tumor
cGroup of 4 patients with right-sided breast tumor